ZA202201362B - Use of dihydroartemisinin and gypenoside-l in manufacture of medicament for resisting tumor - Google Patents
Use of dihydroartemisinin and gypenoside-l in manufacture of medicament for resisting tumorInfo
- Publication number
- ZA202201362B ZA202201362B ZA2022/01362A ZA202201362A ZA202201362B ZA 202201362 B ZA202201362 B ZA 202201362B ZA 2022/01362 A ZA2022/01362 A ZA 2022/01362A ZA 202201362 A ZA202201362 A ZA 202201362A ZA 202201362 B ZA202201362 B ZA 202201362B
- Authority
- ZA
- South Africa
- Prior art keywords
- gypenoside
- dihydroartemisinin
- medicament
- manufacture
- resisting tumor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111301077.9A CN113952350B (en) | 2021-11-04 | 2021-11-04 | Application of dihydroartemisinin and gypenoside-L in preparation of antitumor drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202201362B true ZA202201362B (en) | 2022-04-28 |
Family
ID=79469299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/01362A ZA202201362B (en) | 2021-11-04 | 2022-01-28 | Use of dihydroartemisinin and gypenoside-l in manufacture of medicament for resisting tumor |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113952350B (en) |
| ZA (1) | ZA202201362B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104739824A (en) * | 2013-12-30 | 2015-07-01 | 昆山达人生物医药有限公司 | Use of dihydroartemisinin in preparation of drug for inhibition of tumour growth |
| CN109481454B (en) * | 2018-11-22 | 2021-04-30 | 中国中医科学院中药研究所 | Anti-tumor composition, application of anti-tumor composition in preparation of anti-tumor or cancer cell inhibiting medicine, and anti-tumor medicine |
-
2021
- 2021-11-04 CN CN202111301077.9A patent/CN113952350B/en active Active
-
2022
- 2022-01-28 ZA ZA2022/01362A patent/ZA202201362B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113952350B (en) | 2022-11-25 |
| CN113952350A (en) | 2022-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266623A (en) | Pharmaceutical composition for use in the therapeutic treatment of cancer and complications of cancer | |
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| EP4011371A4 (en) | Pharmaceutical composition producing safe amount of nitric oxide in body and use thereof | |
| EP4119156A4 (en) | Medicament for treatment and/or prevention of cancer | |
| EP3960766A4 (en) | Tumor therapeutic agent and use thereof | |
| ZA202201362B (en) | Use of dihydroartemisinin and gypenoside-l in manufacture of medicament for resisting tumor | |
| EP4099988A4 (en) | Rna-loaded nanoparticles and use thereof for the treatment of cancer | |
| IL308992A (en) | Treatment of cancer in patients with soluble fr-alpha | |
| IL290427A (en) | Articles and methods for administration of therapeutic agents | |
| EP4115902A4 (en) | Combined use of ctb006 and ponatinib | |
| GB202014736D0 (en) | Novel compounds and their use in therapy | |
| GB202019475D0 (en) | Therapeutic compounds and their use | |
| EP4076527A4 (en) | Therapeutic combinations of drugs and methods of using them | |
| EP3957310A4 (en) | Composition and use thereof in preparation of medication for treating cancer | |
| FI4153136T3 (en) | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof | |
| EP4119160A4 (en) | Medicament for treatment and/or prevention of cancer | |
| EP4119159A4 (en) | Medicament for treatment and/or prevention of cancer | |
| EP3943156A4 (en) | Medicinal composition having excellent absorption of drug into living body and excellent chemical stability | |
| EP4114396A4 (en) | Methods of administering elagolix | |
| GB202020359D0 (en) | Pharmaceutical compositions and use thereof in combination therapy for brain cancer | |
| IL311672A (en) | Dioxazines and their use in treatment of gba-related diseases | |
| GB202110932D0 (en) | Novel compounds and their use in therapy | |
| GB202011808D0 (en) | Novel compounds and their use in therapy | |
| GB202003057D0 (en) | Medicament and use thereof | |
| GB202108572D0 (en) | Therapeutic compounds and their use |